Multi-modal analyses of proteomic measurements associated with type 2 diabetes from the Project Baseline Health Study.

Alessandra Breschi¹, Yuliang Wang², Sarah Short², Wilman Luk², David Erani³, Pouya Kheradpour², Peter Cimermancic², Gary J Tong², Jean Philippe Martin², Manway Liu², Lulu Cao², Daniel Liu², Ranee Chatterjee⁴, Lydia Coulter Kwee⁵, Thomas M Snyder², Andrew Han², Katherine Drake², Charles C Kim²

¹Verily Life Sciences, South San Francisco, CA, USA. ale.breschi@gmail.com.

²Verily Life Sciences, South San Francisco, CA, USA.

³Onduo, P.C., Newton, MA, USA.

⁴Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

⁵Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Understanding diabetes at the molecular level can help refine diagnostic approaches and personalized treatment efforts. METHODS: We generated proteomic data from plasma collected from participants enrolled in the longitudinal observational cohort study Project Baseline Health Study (PBHS) (evaluated cohort, n = 738, 27.9% of the total PBHS cohort), and integrated those data with infor…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.